Trial record 1 of 53 for:    "hereditary paraganglioma-pheochromocytoma" OR "Paraganglioma"
Previous Study | Return to List | Next Study

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

This study has suspended participant recruitment.
(Slow Accrual - Adverse Event Assessment)
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: April 21, 2011
Last updated: July 22, 2014
Last verified: July 2014

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced or progressive malignant pheochromocytoma or paraganglioma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Condition Intervention Phase
Extra-adrenal Paraganglioma
Metastatic Pheochromocytoma
Recurrent Pheochromocytoma
Drug: pazopanib hydrochloride
Other: laboratory biomarker analysis
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • True response proportion in patients who receive the study treatment and have advanced malignant pheochromocytomas and paragangliomas [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    Ninety-five percent confidence intervals for the true response proportion will be calculated according to the approach of Duffy and Santner.

Secondary Outcome Measures:
  • Safety profile of pazopanib hydrochloride [ Time Frame: Up to 5 years ] [ Designated as safety issue: Yes ]
    All toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. For each type of adverse event classified as either possibly, probably, or definitely related to study treatment, the proportion of patients experiencing a severe (grade 3 or higher) adverse event will be noted per cycle. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine adverse event patterns.

  • Duration of tumor response [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    Defined for all patients whose tumor met the criteria of complete response (CR) or partial response (PR) (using the RECIST criteria) as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented.

  • Time to treatment failure [ Time Frame: The time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal, assessed up to 5 years ] [ Designated as safety issue: No ]
  • Progression-free survival time [ Time Frame: The time from registration to documentation of disease progression, assessed up to 5 years ] [ Designated as safety issue: No ]
  • Overall survival time [ Time Frame: The time from registration to death due to any cause, assessed up to 5 years ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Association between CYP isoforms and the maximum pazopanib hydrochloride plasma level achieved [ Time Frame: Baseline and during the first course of treatment ] [ Designated as safety issue: No ]
  • Tumor response associated with plasma pazopanib hydrochloride levels achieved [ Time Frame: Baseline and during the first course of treatment ] [ Designated as safety issue: No ]
    A two sample Wilcoxon rank sum test will be used.

  • Severe toxicities leading to pazopanib hydrochloride dose reductions and the associated maximum pazopanib hydrochloride level achieved [ Time Frame: Baseline and during the first course of treatment ] [ Designated as safety issue: No ]
    A two sample Wilcoxon rank sum test will be used.

  • Changes in urinary catecholamine and metanephrine levels [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Pazopanib hydrochloride-induced changes in urinary catecholamine and/or metanephrine levels and the association with objective tumor response [ Time Frame: Baseline to during the first course of treatment ] [ Designated as safety issue: No ]
  • Tumor response and somatic mutational status [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Tumor response and tumor expression levels of HIF-1a, VEGF-R (total and phospho-) assessed via immunohistochemistry [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Tumor microvessel density assessed using MECA-32 immunohistochemical staining [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 38
Study Start Date: May 2011
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (pazopanib hydrochloride)
Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: pazopanib hydrochloride
Given PO
Other Names:
  • GW786034B
  • Votrient
Other: laboratory biomarker analysis
Correlative studies

Detailed Description:


I. To assess the anti-tumor activity (in terms of the tumor response rate using the Response Evaluation Criteria in Solid Tumors [RECIST] criteria) of pazopanib (pazopanib hydrochloride) (GW786034) in patients with advanced malignant pheochromocytomas and paragangliomas.


I. To assess safety profile of pazopanib. II. To assess duration of tumor response. III. To assess time to treatment failure. IV. To assess progression-free survival time. V. To assess overall survival time.


I. For patients with secretory tumors, to examine changes in urinary catecholamine and/or metanephrine levels.

II. For patients with secretory tumors, to examine whether pazopanib-induced changes in urinary catecholamine and/or metanephrine levels during the first cycle of treatment may be associated with objective tumor response.

III. To examine associations between tumor response and somatic mutational status in archived tumors, or germline mutational status in patient's peripheral blood mononuclear cells, (presence of succinate dehydrogenase complex subunit D [SDHD], succinate dehydrogenase complex subunit B [SDHB], ret proto-oncogene [RET], von Hippel-Lindau tumor suppressor [VHL], neurofibromatosis type-1).

IV. To examine associations between tumor response and tumor expression levels of angiogenic and vascular markers including hypoxia inducible factor 1, alpha (HIF-1a), vascular endothelial growth factor receptor (VEGF-R) (total and phospho-) and microvessel density in archival tumor tissue.

IV. To examine whether the extent of tumor response/regression may be correlated with plasma pazopanib (GW786034) concentration achieved after the third cycle (first cycle after run-in cycles) of pazopanib (GW786034) therapy.

OUTLINE: This is a multicenter study.

Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo urine and blood sample collection at baseline and periodically during study for correlative studies.

After completion of study therapy, patients are followed up every 3-6 months for up to 5 years.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed malignant secretory or non-secretory pheochromocytoma or paraganglioma that is unresectable and deemed inappropriate for alternative local regional therapeutic approaches
  • Objective evidence of tumor progression =< 185 days prior to registration as assessed by:

    • Unequivocal progression of objectively measured disease on successive appropriate imaging (e.g. computed tomography [CT] scan); in cases of uncertainty of tumor progression, the principal investigator of the study will be available to assist in decisions
  • Measurable disease defined as:

    • At least one non-nodal lesion whose longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with CT scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI); and/or
    • A lymph node whose short axis must be > 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm)
    • Note: Tumor lesions in a previously irradiated area are not considered measurable disease
  • Life expectancy > 24 weeks
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Leukocytes >= 3,000/uL
  • Absolute neutrophil count >= 1,500/uL
  • Platelets >= 100,000/uL
  • Hemoglobin >= 9 g/dL (5.6 mmol/L); transfusions not permitted =< 7 days of registration
  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except in cases of Gilbert's syndrome, where indirect bilirubin may be elevated, but the direct bilirubin remains within 1.5 x ULN)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN
  • NOTE: Subjects who have both bilirubin > ULN and AST/ALT > ULN are not eligible
  • Alkaline phosphatase =< 2.5 x ULN
  • Creatinine =< 1.5 mg/dL (133 umol/L) or within normal institutional limits OR creatinine clearance >= 50 mL/min/1.73m^2 for subjects with creatinine levels about institutional normal
  • Urine protein/creatinine ratio =< 1 OR 24-hour urine < 1 gram
  • Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.2 x ULN unless a subject is receiving Coumadin and has stable INR which is in range for the desired level of anticoagulation
  • Blood pressure (BP) < 140 mmHg (systolic) and < 90 mmHg (diastolic); initiation or adjustment of BP medication is permitted prior to registration provided that the average of three BP readings at a visit prior to registration is < 140/90 mmHg

    • NOTE: All patients with secretory pheochromocytomas or paragangliomas are required to: 1) be evaluated in consultation by a hypertension specialist (at the registering institution) with experience in the management of hypertension in the setting of catecholamine-secreting tumors (usually an endocrinologist, nephrologist, or a cardiologist), and in the setting of hormone-associated hypertension 2) receive alpha- and beta-adrenergic blockade for at least 7 days prior to initiation of pazopanib (GW786034); the hypertension specialist of record for each patient should be committed to following the patient during the clinical study with evaluation by said specialist required at all run-in cycle evaluations (cycles 1 and 2) and also after the first continuous dosing cycle (cycle 3) and thereafter on an as needed basis
  • Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
  • Ability to understand and the willingness to sign a written informed consent document
  • Willingness to donate blood and tissue for correlative marker studies

Exclusion Criteria:

  • Any of the following:

    • Pregnant women
    • Nursing women
    • Men or women of childbearing potential who are unwilling to employ adequate contraception NOTE: breastfeeding should be discontinued if the mother is treated with pazopanib (GW786034)
  • Any of the following:

    • Chemotherapy/systemic therapy =< 4 weeks prior to registration
    • Radiotherapy =< 4 weeks prior to registration
    • Surgery =< 4 weeks prior to registration
    • Nitrosoureas or mitomycin C =< 6 weeks prior to registration
    • Those who have not recovered from adverse events due to agents administered more than 4 weeks earlier NOTE: Concurrent therapy with octreotide is allowed providing that tumor progression on this therapy has been demonstrated; concurrent therapy with bisphosphonates (e.g. zoledronic acid) or denosumab is also allowed.

NOTE: An unlimited number of prior chemotherapeutic or biologic therapies for malignant pheochromocytoma or paraganglioma is permitted; this includes prior anti-angiogenesis therapies such as tyrosine kinase inhibitors

  • Any other ongoing investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib (GW786034) or other agents used in the study
  • Any of the following:

    • Corrected QT (QTc) prolongation (defined as a QTc interval >= 500 msecs)
    • Left ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN)
    • Frequent ventricular ectopy
    • Evidence of ongoing myocardial ischemia
  • Receiving prohibited cytochrome P450 (CYP) interactive concomitant medications within 7 days prior to registration
  • Any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain pazopanib (GW786034)
  • Receiving any medications or substances with risk of torsades de pointes; note: medications or substances with risk of torsades de pointes are prohibited; medications or substances with possible or conditional risk of torsades de pointes may be used while on study with extreme caution and careful monitoring; patients receiving these later cautionary agents must be monitored serially with electrocardiogram (ECG) weekly during the run-in and first cycle of therapy and at each evaluation thereafter NOTE: These medications should be discontinued or replaced with drugs that do not carry these risks, if possible
  • Any of the following conditions:

    • Active peptic ulcer disease
    • Known intraluminal bowel metastatic lesions
    • Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or other gastrointestinal conditions which increase the risk of perforation
    • History of new abdominal fistula, gastrointestinal perforation or intra-abdominal abscess =< 84 days prior to registration; enrollment of patients with chronic/canalized fistulous tracts (present for > 84 days) is allowed
    • Serious or non-healing wound, ulcer, or bone fracture
    • History of familial QTc prolongation syndrome
  • Any of the following conditions =< 185 days prior to registration:

    • Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
    • Cardiac arrhythmia
    • Admission for unstable angina
    • Cardiac angioplasty or stenting
    • Coronary artery bypass graft surgery
    • Pulmonary embolism, untreated deep venous thrombosis (DVT) or DVT which has been treated with therapeutic anticoagulation < 42 days
    • Arterial thrombosis
    • Symptomatic peripheral vascular disease
    • Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system
  • Hemoptysis in excess of 2.5 mL (1/2 teaspoon) =< 60 days prior to registration
  • Any of the following:

    • Known active and/or untreated brain metastases
    • Brain metastases requiring ongoing therapy (e.g. corticosteroids)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements
  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy
  • Require heparin other than low-molecular weight heparin
  • Prior use of pazopanib (GW786034)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01340794

United States, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
United States, Florida
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224-9980
United States, Maryland
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States, 21287
United States, Michigan
University of Michigan University Hospital
Ann Arbor, Michigan, United States, 48109
University of Michigan
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Metro-Minnesota CCOP
Saint Louis Park, Minnesota, United States, 55416
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Texas
M D Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
China, Hong Kong
Chinese University of Hong Kong-Prince of Wales Hospital
Shatin, Hong Kong, China, OX1 3UJ
National University Hospital
Singapore, Singapore, 119074
Sponsors and Collaborators
Principal Investigator: Keith Bible Mayo Clinic
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI) Identifier: NCT01340794     History of Changes
Other Study ID Numbers: NCI-2011-02588, NCI-2011-02588, CDR0000699430, MAYO-MC107B, MC107B, 8783, P30CA015083, N01CM00039, N01CM00071, N01CM00099
Study First Received: April 21, 2011
Last Updated: July 22, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Paraganglioma, Extra-Adrenal
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue processed this record on July 28, 2014